IKIsabella Kamholtz

Isabella Kamholtz

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Isabella Kamholtz has a total of 11 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Cannabidiol and Epigenetic Regulation of Hair Follicle Cycling: Receptor Crosstalk and Transcriptional Control in Alopecia

    by Simonetta I. Gaumond, Isabella Kamholtz, Lina M. Ferrari, Kevin Núño, Madisyn Opstal, Joaquin J. Jimenez

    Cannabidiol (CBD) is a non-intoxicating phytocannabinoid with increasingly recognized effects on cutaneous and hair follicle (HF) biology. This narrative review evaluates CBD-responsive signaling and its intersection with transcriptional, epigenetic, and post-transcriptional mechanisms relevant to HF cycling and alopecia, with particular emphasis on the hierarchy of experimental evidence. Available data indicate that CBD does not exert a uniformly pro-growth effect, but instead produces concentration-, compartment-, and context-dependent responses. In human HFs, submicromolar CBD primarily demonstrates anti-inflammatory activity, whereas micromolar exposure suppresses hair shaft production and promotes catagen through TRPV4-dependent Ca2+ signaling. CBD also modulates adenosine and Wnt/β-catenin pathways and can restore β-catenin expression in human dermal papilla cells under inhibitory conditions. Beyond acute receptor signaling, CBD influences DNA methylation, histone modifications, miRNA networks, and transcriptional regulators including PPARγ and AhR. However, most of this evidence derives from non-follicular systems, and direct CBD-induced epigenetic remodeling of human HFs has not been demonstrated. Among alopecia subtypes, AGA has the strongest mechanistic and preliminary clinical rationale, whereas evidence in AA and scarring alopecia remains largely indirect. Translation is further limited by uncertain intrafollicular CBD exposure, formulation-dependent delivery, and the absence of controlled clinical efficacy data. CBD should therefore be viewed as a context-dependent regulator of follicular signaling rather than an established hair growth treatment. Future studies should define follicular pharmacokinetics, establish concentration–response relationships, and test pathway causality in intact human HFs and disease-specific models.

  • Open Access

    Chemotherapy-Induced Alopecia in Breast Cancer Patients: Treatment-Specific Incidence and Risk of Persistent Hair Loss

    by Simonetta I. Gaumond, Sophie Shrestha, Isabella Kamholtz, Gabriela E. Beraja, Joaquin J. Jimenez

    Chemotherapy-induced alopecia (CIA) is one of the most common and visible toxicities of breast cancer treatment, yet its true incidence, severity, and long-term outcomes remain inconsistently reported. Although CIA is frequently cited as affecting approximately 65% of patients and persistent alopecia has historically been considered uncommon (1–15%), emerging data suggest a substantially greater burden. We conducted a scoping review of PubMed, EMBASE, SCOPUS, and Cochrane databases to synthesize regimen-specific evidence on the incidence, severity, and persistence of CIA in breast cancer patients. Anthracycline- and taxane-based regimens were associated with the highest risk, with severe alopecia reported in more than 70% of patients and rates approaching 90–100% in combination regimens. Cyclophosphamide further amplified acute CIA when combined with doxorubicin, with reported incidence up to 93%. In contrast, capecitabine and vinorelbine were consistently associated with lower alopecia incidence. Importantly, CIA was not uniformly reversible. Persistent CIA (pCIA) occurred in up to 67% of patients treated with doxorubicin-based regimens and nearly 50% of those receiving docetaxel combinations, substantially higher than historically reported. Despite its high frequency and potential permanence, CIA remains underreported in oncology trials and insufficiently addressed in survivorship care. Recognizing CIA as both an acute toxicity and a potential long-term survivorship concern underscores the need for standardized reporting, longitudinal follow-up, and development of effective preventive strategies in breast cancer care.


  • Open Access

    Cytokine-Targeting Biologic Therapies for Alopecia Areata: A Comprehensive Review of Mechanism of Action, Clinical Efficacy, and Adverse Events

    by Simonetta I. Gaumond, Isabella Kamholtz, Joaquin J. Jimenez

    Background: Alopecia areata (AA) is an autoimmune disease affecting 2% of the global population, often causing localized scalp hair loss that can progress to alopecia totalis or universalis. While corticosteroids and JAK inhibitors are effective, their significant side effects highlight the need for safer, more targeted treatments. Recently, biologics have gained attention as potential treatments for AA. Methods: A review of clinical trials, case series, and case reports published on PubMed was conducted to assess the efficacy of cytokine-targeting biologics for the treatment of AA. Data on the mechanism of action, treatment outcomes, and safety were extracted and analyzed. Results: Cytokine-targeting biologics identified included Dupilumab, Secukinumab, Tralokinumab, Etanercept, Ustekinumab, Infliximab, Adalimumab, and Tildrakizumab. Dupilumab and ustekinumab demonstrated strong efficacy, with dupilumab showing significant regrowth in 89% of cases and ustekinumab in all patients. Tralokinumab demonstrated a 33.75% improvement, with no patients achieving SALT50. Limited efficacy was observed with secukinumab, tildrakizumab, and adalimumab, with 71.4%, 77.8%, and 50% of patients, respectively, showing no response. Disease worsening was observed in patients who received etanercept (29%) and infliximab (50%). Conclusions: Further research is necessary to optimize treatment protocols, identify predictive biomarkers, and, crucially, discover novel and more effective cytokine targets to advance biologics as a cornerstone therapy for AA.


  • Open Access

    Parallel Toxicities: A Comparative Analysis of Chemotherapy-Induced Neutropenia and Alopecia

    by Simonetta I. Gaumond, Karen J. Lee, Peyton V. Warp, Isabella Kamholtz, Emilee M. Dreifus, Joaquin J. Jimenez

    Chemotherapy-induced neutropenia (CIN) and chemotherapy-induced alopecia (CIA) are significant toxicities affecting cancer patients. CIN is a potentially fatal complication of chemotherapy caused by myelosuppression and increased infection susceptibility, while CIA, although not fatal, severely affects treatment adherence and mental health. This study provides a comprehensive comparative analysis of CIN and CIA, focusing on patient, disease, treatment, and genetic risk factors. Key risk factors for CIN and CIA include age, poor performance status, body mass index (BMI), laboratory abnormalities, and pre-existing comorbidities. Both toxicities were significantly associated with breast cancer patients, although CIN patients were more likely to have hematological cancer, and CIA patients were more likely to have solid tumors. Notably, anthracyclines, alkylators, and taxanes frequently induce both toxicities, although their timelines and clinical implications differed. There was no clear overlap between genetic predispositions and toxicities beyond single-nucleotide polymorphisms (SNPs) in the ABCB1 gene. This is the first study to directly compare CIN and CIA, offering insights into personalized oncology care. Understanding the risk factors implicated in the development of CIN and CIA will enable physicians to manage patient outcomes.


  • Open Access

    Chemotherapy-Induced Alopecia in Ovarian Cancer: Incidence, Mechanisms, and Impact Across Treatment Regimens

    by Simonetta I. Gaumond, Gabriela E. Beraja, Isabella Kamholtz, Lina M. Ferrari, Rami H. Mahmoud, Joaquin J. Jimenez

    Background/Objectives: Ovarian cancer is the fifth most common cancer among women, with an estimated 19,680 new cases projected in 2024. Adjuvant chemotherapy remains the standard treatment for epithelial ovarian cancers but is frequently associated with adverse events, such as chemotherapy-induced alopecia (CIA). CIA is a particularly distressing side effect that significantly affects the body image, self-esteem, and quality of life of patients. Unfortunately, CIA remains underexplored in patients with ovarian cancer. Methods: This scoping review analyzed PubMed- and EMBASE-indexed studies investigating the incidence, severity, and mechanisms of CIA in ovarian cancer patients. Eighteen studies were included for analysis. Results: Our analysis identified platinum-based compounds, taxanes, and topoisomerase I inhibitors as the agents most strongly correlated with severe alopecia, particularly in combination regimens such as carboplatin–paclitaxel (CP), and cyclophosphamide, adriamycin, and cisplatin (CAP). Among the monotherapies, taxanes, including paclitaxel and docetaxel, posed the highest risk of CIA. Mild-to-moderate alopecia was observed in patients treated with gemcitabine or pegylated liposomal doxorubicin. Alternative factors such as dosing schedules and prior chemotherapy exposure also significantly influence CIA severity. Conclusions: Given the profound psychosocial impact of CIA, optimizing treatment protocols to reduce the severity of alopecia without compromising therapeutic efficacy is crucial. These findings offer insights that may guide future therapeutic strategies for improving patient outcomes and quality of life.